Literature DB >> 31028876

Clinical significance of lnc-AC145676.2.1-6 and lnc-TGS1-1 and their variants in western Chinese tuberculosis patients.

Hao Bai1, Qian Wu1, Xuejiao Hu1, Tao Wu1, Jiajia Song1, Tangyuheng Liu1, Zirui Meng1, Mengyuan Lv1, Xiaojun Lu1, Xuerong Chen2, Yanhong Zhou1, Binwu Ying3.   

Abstract

OBJECTIVES: Tuberculosis (TB) remains a global public health problem. Recent studies have implicated long non-coding RNAs and their variants as possibly playing important roles in TB. The aim of this study was to assess the clinical relevance of lnc-AC145676.2.1-6 and lnc-TGS1-1 and their variants in a western Chinese population.
METHODS: This case-control study included 467 TB patients and 473 healthy controls from West China Hospital. The expression levels of lnc-AC145676.2.1-6 and lnc-TGS1-1 were analyzed by reverse transcriptase quantitative real-time PCR. Single-nucleotide polymorphism genotyping was performed using a custom-designed 2 × 48-Plex SNPscan kit.
RESULTS: It was observed that lnc-AC145676.2.1-6 and lnc-TGS1-1 expression levels were both obviously down-regulated in TB patients. In addition, a lower expression level of lnc-TGS1-1 was associated with the presence of thrombocytopenia in TB patients during anti-TB treatment, and the homozygous CC genotype of rs4737420 correlated with a decreased risk of leukopenia, compared with individuals with the T allele (TT/CT genotype), in the dominant mode.
CONCLUSIONS: For the first time, potential TB-associated promoting effects were identified for the decreased expression levels of lnc-AC145676.2.1-6 and lnc-TGS-1, while lnc-TGS1-1 and its variant rs4737420 may be predictive indicators of anti-TB drug-induced adverse drug reactions. Larger validation studies on different populations are warranted to confirm these findings.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Adverse drug reactions; Genetic variants; Long non-coding RNA; Tuberculosis

Mesh:

Substances:

Year:  2019        PMID: 31028876     DOI: 10.1016/j.ijid.2019.04.018

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  7 in total

Review 1.  Long Non-coding RNAs in Tuberculosis: From Immunity to Biomarkers.

Authors:  Xianyi Zhang; Chan Chen; Yuzhong Xu
Journal:  Front Microbiol       Date:  2022-05-11       Impact factor: 6.064

2.  Association of ficolin-1 and ficolin-3 gene variation and pulmonary tuberculosis susceptibility in a Chinese population.

Authors:  Ye Li; En-Qing You; Wen-Hong Lin; Xiao-Ning Liu; De-Pei Shen; Xin-Li Zhang; Dong-Chun Ma; Hong-Miao Li
Journal:  J Clin Lab Anal       Date:  2021-02-16       Impact factor: 2.352

3.  Screening of Long Non-coding RNAs Biomarkers for the Diagnosis of Tuberculosis and Preliminary Construction of a Clinical Diagnosis Model.

Authors:  Juli Chen; Lijuan Wu; Yanghua Lv; Tangyuheng Liu; Weihua Guo; Jiajia Song; Xuejiao Hu; Jing Li
Journal:  Front Microbiol       Date:  2022-03-03       Impact factor: 5.640

Review 4.  The Roles of Host Noncoding RNAs in Mycobacterium tuberculosis Infection.

Authors:  Li Wei; Kai Liu; Qingzhi Jia; Hui Zhang; Qingli Bie; Bin Zhang
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

5.  Novel Long Non-coding RNA and LASSO Prediction Model to Better Identify Pulmonary Tuberculosis: A Case-Control Study in China.

Authors:  Zirui Meng; Minjin Wang; Shuo Guo; Yanbing Zhou; Mengyuan Lyu; Xuejiao Hu; Hao Bai; Qian Wu; Chuanmin Tao; Binwu Ying
Journal:  Front Mol Biosci       Date:  2021-05-25

6.  Genetic and Functional Evaluation of the Role of FOXO1 in Antituberculosis Drug-Induced Hepatotoxicity.

Authors:  Jingwei Zhang; Lin Jiao; Jiajia Song; Tao Wu; Hao Bai; Tangyuheng Liu; Zhenzhen Zhao; Xuejiao Hu; Binwu Ying
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-19       Impact factor: 2.629

Review 7.  The Role of microRNAs and Long Non-Coding RNAs in the Regulation of the Immune Response to Mycobacterium tuberculosis Infection.

Authors:  Manikuntala Kundu; Joyoti Basu
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.